R&D channel feed

Gilead re­veals plans to put an­oth­er $11B in­to US man­u­fac­tur­ing

2 months ago
Pharma
Manufacturing

Theri­va’s on­colyt­ic virus suc­ceeds in pan­cre­at­ic can­cer study, but stock falls

2 months ago

CRISPR Ther­a­peu­tic­s' gene edit­ing ther­a­py re­duces bad cho­les­terol and triglyc­erides by as much as 80%

2 months ago
Cell/Gene Tx

Biotech stocks plunge and in­dus­try fig­ures left to won­der af­ter Prasad's FDA ap­point­ment

2 months ago

Marea heads to Phase 2b af­ter up­dat­ed bio­mark­er da­ta show CV drug’s promise

2 months ago

Ver­tex paus­es study of mR­NA ther­a­py for cys­tic fi­bro­sis

2 months ago

Aldeyra plots third FDA fil­ing for dry eye dis­ease drug af­ter lat­est Phase 3 da­ta

2 months ago

PTC's Hunt­ing­ton’s study suc­ceeds, but ac­cel­er­at­ed ap­proval un­cer­tain

2 months ago

Even as ques­tions grow over RFK Jr.'s vac­cine pol­i­cy, BioN­Tech does­n't see ‘near-term’ im­pact

2 months ago
Pharma
FDA+

Re­cur­sion cuts near­ly half of its pipeline, in­clud­ing its most ad­vanced pro­gram

2 months ago
AI

J&J's eye dis­ease gene ther­a­py bo­ta-vec fails in Phase 3 tri­al

2 months ago
Cell/Gene Tx

Ear­ly bits of in vi­vo CAR-T hu­man da­ta emerge from biotech tri­als in Chi­na

2 months ago
China
Cell/Gene Tx

Ex­clu­sive: Topas claims suc­cess in ear­ly test of 'im­mune tol­er­ance' ther­a­py for celi­ac dis­ease

2 months ago

Ex­clu­sive: Ver­tex drops AAV gene ther­a­py re­search, tR­NA ther­a­py part­ner­ship

2 months ago
Cell/Gene Tx

FDA with­draws two fi­nal guid­ances, pulls com­pli­ance dead­lines for bone al­lo­graft mak­ers

2 months ago
Pharma
FDA+

Feng Zhang’s pro­tein nanopar­ti­cle start­up Aera Ther­a­peu­tics turns to lipid nanopar­ti­cles to jump­start its pipeline

2 months ago
Cell/Gene Tx

Drug­mak­ers ex­ploit can­cer’s ‘lethal­i­ties’ to make next class of tar­get­ed ther­a­pies, with first re­sults for Wern­er drug

2 months ago

In­vestors un­veil plans for $1.3B can­cer hub in Lon­don sub­urbs

2 months ago
Manufacturing

Mod­er­na, fac­ing rev­enue miss­es and po­lit­i­cal head­winds, dis­ap­points Wall Street

2 months ago
Pharma

CROs raise the alarm as clients de­lay R&D plans over fund­ing, tar­iff wor­ries

2 months ago
Outsourcing

Mod­er­na ex­pands ef­fort to rein in costs in an ‘un­cer­tain en­vi­ron­ment’

2 months ago
Pharma

Sci­en­tists alarmed about fu­ture of can­cer re­search; TIG­IT, CAR-NK and more from #AACR25

2 months ago

Ar­tios drug ex­ploits ‘repli­ca­tion stress’ in can­cer, shrink­ing sub­set of tu­mors in ear­ly study

2 months ago
Startups

No­var­tis con­tin­ues earn­ings win­ning streak as it rais­es 2025 sales ex­pec­ta­tions

2 months ago
Pharma
First page Previous page 567891011 Next page Last page
A service from the Financial Times